Bruker Daltonics Announces Convenient Prespotted AnchorChip.

BEIJING -- At the 2004 Human Proteomics Organization (HUPO) Conference, Bruker Daltonics Inc., an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), and Eppendorf AG, Germany, today announce the Prespotted AnchorChip(TM), a second-generation disposable AnchorChip MALDI target for gel-based and LC-MALDI-based expression proteomics.

The novel Prespotted AnchorChip eliminates any cross-contamination from previous samples, eliminates laborious calibration spot preparation, and significantly reduces sample preparation time, while it maintains unrivalled sensitivity. It now offers in a convenient disposable format the well-established AnchorChip 10-fold to 100-fold sensitivity increase.

The Prespotted AnchorChip comes in a 384 sample microtitre plate (MTP) format with additional 96 calibrant spots, all conveniently pre-spotted with matrix. Each chip is delivered under inert gas in a container that can also be used for sample archiving after the analysis. The Prespotted AnchorChip provides for the first time a polymer-based sample target for MALDI-TOF(/TOF) instruments with a flatness comparable to steel targets resulting in unchanged, excellent mass accuracy. Pre-spotted matrix and the calibrant spots enable users to simply apply aqueous peptide and protein digest samples directly to the target. Additional calibrant spot preparations or the use of organic solvents and matrices can be omitted altogether. The individual barcode on each chip allows effective and secure sample tracking.

The Prespotted AnchorChip has been developed in collaboration with Eppendorf AG, and is exclusively available for Bruker Daltonics MALDI customers. Eppendorf contributed their know-how in "smart plastics" and their renowned state-of-the-art production processes for this customized proteomics chip. The Prespotted AnchorChip offers reliable, quality-controlled conditions for convenient MALDI-TOF(/TOF) sample preparation with highest reproducibility in expression and quantitative proteomics.

Dr. Michael Schubert, Vice President for R&D of Bruker Daltonics, explained: "The Prespotted AnchorChip represents a crucial improvement in reproducible, high-quality MALDI sample preparation for proteomics, which is essential for larger validation or comparison studies, particularly in the pharmaceutical industry. It all but eliminates any significant risk of memory effects or cross contamination, and it makes MALDI sample preparation far more convenient and less error-prone."

He continued: "Now, the entire process from sample collection, through sample clean-up and MALDI sample preparation is based on standardized disposables for validation purposes. Yet, we maintain the excellent mass accuracy and highest sensitivity of our original steel AnchorChips. We are very pleased to offer our customers this high-performance chip together with Eppendorf AG, whose excellent reputation for highest quality life-science consumables perfectly fits into our own product philosophy."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on x-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit: www.bruker-biosciences.com

ABOUT EPPENDORF

Eppendorf AG is a leading supplier of systems and research tools for the biotechnology industry worldwide with a wide range of products including instruments, consumables and reagents. Applications include cell manipulation, complete PCR systems, liquid handling, purification of DNA, liquid handling and centrifugation. Eppendorf employs more than 1,700 employees worldwide. In 2003, the company achieved sales of more than 270 million Euro with earnings before interest and tax (EBIT) of approx. 36 million Euro. For more information: www.eppendorf.com

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.